Inhibrx Biosciences, Inc.
INBX
$14.93
-$0.28-1.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 703.84% | 786.99% | -- | -- | -- |
| Total Depreciation and Amortization | 107.01% | 91.86% | -- | -- | -- |
| Total Amortization of Deferred Charges | -57.69% | -32.50% | -- | -- | -- |
| Total Other Non-Cash Items | -6,944.89% | -7,378.23% | -- | -- | -- |
| Change in Net Operating Assets | 242.04% | 265.88% | -- | -- | -- |
| Cash from Operations | 17.19% | -12.33% | -- | -- | -- |
| Capital Expenditure | 73.65% | 43.46% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 73.65% | 43.46% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -70.26% | -45.43% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -51.67% | -11,571.27% | -- | -- | -- |
| Cash from Financing | -39.13% | -65.85% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -187.18% | -3,814.44% | -- | -- | -- |